DK3227454T3 - Fremgangsmåde til manipulering af niveauet af glycanindhold på et glycoprotein - Google Patents
Fremgangsmåde til manipulering af niveauet af glycanindhold på et glycoprotein Download PDFInfo
- Publication number
- DK3227454T3 DK3227454T3 DK15816598.5T DK15816598T DK3227454T3 DK 3227454 T3 DK3227454 T3 DK 3227454T3 DK 15816598 T DK15816598 T DK 15816598T DK 3227454 T3 DK3227454 T3 DK 3227454T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycoprotein
- manipulating
- procedure
- level
- glycan content
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C07K16/242—Lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462085759P | 2014-12-01 | 2014-12-01 | |
| PCT/US2015/063271 WO2016089919A1 (en) | 2014-12-01 | 2015-12-01 | Process for manipulating the level of glycan content of a glycoprotein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3227454T3 true DK3227454T3 (da) | 2020-04-14 |
Family
ID=55024253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15816598.5T DK3227454T3 (da) | 2014-12-01 | 2015-12-01 | Fremgangsmåde til manipulering af niveauet af glycanindhold på et glycoprotein |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10167492B2 (enExample) |
| EP (2) | EP3680344A1 (enExample) |
| JP (4) | JP6698681B2 (enExample) |
| KR (1) | KR102623965B1 (enExample) |
| CN (1) | CN107109455B (enExample) |
| AU (5) | AU2015355087C1 (enExample) |
| CA (1) | CA2969225C (enExample) |
| CL (1) | CL2017001369A1 (enExample) |
| CY (1) | CY1123247T1 (enExample) |
| DK (1) | DK3227454T3 (enExample) |
| EA (2) | EA202091598A3 (enExample) |
| ES (1) | ES2784503T3 (enExample) |
| HU (1) | HUE049201T2 (enExample) |
| IL (2) | IL276165B (enExample) |
| LT (1) | LT3227454T (enExample) |
| MX (1) | MX385409B (enExample) |
| PL (1) | PL3227454T3 (enExample) |
| PT (1) | PT3227454T (enExample) |
| SG (2) | SG11201704351WA (enExample) |
| SI (1) | SI3227454T1 (enExample) |
| WO (1) | WO2016089919A1 (enExample) |
| ZA (2) | ZA201703729B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2784503T3 (es) | 2014-12-01 | 2020-09-28 | Amgen Inc | Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína |
| EP4310503A3 (en) | 2015-12-30 | 2024-03-20 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
| US12503700B2 (en) * | 2017-03-14 | 2025-12-23 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| SG11201909087PA (en) * | 2017-03-31 | 2019-10-30 | Boehringer Ingelheim Int | Perfusion medium |
| WO2019105444A1 (zh) * | 2017-11-30 | 2019-06-06 | 正大天晴药业集团南京顺欣制药有限公司 | 蛋白质的生产方法 |
| JP2021519068A (ja) * | 2018-03-26 | 2021-08-10 | アムジェン インコーポレイテッド | 細胞培養において産生される抗体の総非フコシル化グリコフォーム |
| AU2019274782A1 (en) * | 2018-05-24 | 2020-12-03 | Ares Trading S.A. | Method for controlling the afucosylation level of a glycoprotein composition |
| MA52783A (fr) | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
| WO2020055900A1 (en) | 2018-09-11 | 2020-03-19 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
| HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt. | Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
| SG11202104092UA (en) | 2018-11-13 | 2021-05-28 | Janssen Biotech Inc | Control of trace metals during production of anti-cd38 antibodies |
| EP3906257A4 (en) | 2018-12-31 | 2022-09-14 | Momenta Pharmaceuticals, Inc. | USTEKINUMAB PRODUCTION PROCESSES |
| JP2022523063A (ja) * | 2019-01-30 | 2022-04-21 | アムジエン・インコーポレーテツド | アフリベルセプトの属性、並びにその特性決定及び修飾方法 |
| KR20230002024A (ko) | 2019-05-06 | 2023-01-05 | 암젠 인크 | 항체 효과기 기능의 조절 |
| JP2020188737A (ja) * | 2019-05-23 | 2020-11-26 | 東ソー株式会社 | 抗体依存性細胞傷害活性が向上した抗体の製造方法 |
| AU2020355251A1 (en) | 2019-09-26 | 2022-04-21 | Amgen Inc. | Methods of producing antibody compositions |
| EP4058547A1 (en) | 2019-11-15 | 2022-09-21 | Lonza Ltd. | Process and system for producing an inoculum |
| WO2022026451A1 (en) * | 2020-07-30 | 2022-02-03 | Amgen Inc. | Cell culture media and methods of making and using the same |
| US20230313259A1 (en) * | 2020-08-14 | 2023-10-05 | Bristol-Myers Squibb Company | Manufacturing process for protein |
| US20240043501A1 (en) | 2020-10-15 | 2024-02-08 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
| AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
| WO2023161885A1 (en) * | 2022-02-25 | 2023-08-31 | Kashiv Biosciences, Llc | A process for improving polypeptide expression in mammalian cell culture |
| WO2024220916A1 (en) | 2023-04-20 | 2024-10-24 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025036924A1 (en) * | 2023-08-16 | 2025-02-20 | Glaxosmithkline Intellectual Property Limited | Method of controlling antibody glycosylation profile |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| ATE236249T1 (de) | 1989-09-12 | 2003-04-15 | Hoffmann La Roche | Tfn-bindende proteine |
| US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
| US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
| US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| US5096816A (en) | 1990-06-05 | 1992-03-17 | Cetus Corporation | In vitro management of ammonia's effect on glycosylation of cell products through pH control |
| US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
| US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
| US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| AU708239B2 (en) | 1995-06-29 | 1999-07-29 | Immunex Corporation | Cytokine that induces apoptosis |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| JP2001120262A (ja) | 1999-10-26 | 2001-05-08 | Welfide Corp | 生理活性物質の産生増強方法 |
| AU1920301A (en) | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| DK1248802T3 (da) | 2000-05-26 | 2004-11-15 | Bristol Myers Squibb Co | Oplöselige CTLA4-mutantmolekyler og anvendelser deraf |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| DE10312765A1 (de) | 2003-03-21 | 2004-09-30 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US7300773B2 (en) * | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070231895A1 (en) | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| AU2006324163B2 (en) | 2005-12-08 | 2013-05-02 | Amgen Inc. | Improved production of glycoproteins using manganese |
| WO2007081031A1 (ja) * | 2006-01-16 | 2007-07-19 | Hokkaido University | 糖転移酵素阻害剤 |
| US20100166741A1 (en) * | 2006-07-13 | 2010-07-01 | Genentech , Inc. | Altered br-3 binding polypeptides |
| BRPI0714212B8 (pt) | 2006-07-13 | 2021-05-25 | Wyeth Corp | método de produzir uma glicoproteína em uma cultura celular |
| FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
| CA2666317C (en) | 2006-11-03 | 2013-08-06 | Wyeth | Glycolysis-inhibiting substances in cell culture |
| EP2924113B1 (en) | 2007-03-02 | 2019-04-10 | Wyeth LLC | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2137320A4 (en) * | 2007-03-30 | 2010-06-16 | Centocor Ortho Biotech Inc | HIGH-EXPRESSION CLONES OF MAMMALIAN CELLS WITH A FLUORESCENT PROTEIN A OR G |
| AU2008240080A1 (en) | 2007-04-16 | 2008-10-23 | Momenta Pharmaceuticals, Inc. | Defined glycoprotein products and related methods |
| WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| ES2362990T5 (es) | 2007-06-15 | 2017-07-20 | Amgen Inc. | Métodos de tratamiento de medios de cultivo celular para su uso en un biorreactor |
| US20120277165A1 (en) | 2009-06-05 | 2012-11-01 | Collins Brian E | Methods of modulating fucosylation of glycoproteins |
| AU2011317088B2 (en) | 2010-10-20 | 2016-01-21 | Eisai, Inc. | Anti-folate receptor alpha antibody glycoforms |
| WO2012115874A1 (en) | 2011-02-23 | 2012-08-30 | Amgen Inc. | Cell culture media for uvc exposure and methods related thereto |
| AU2012226398B9 (en) * | 2011-03-06 | 2017-04-13 | Merck Serono S.A. | Low fucose cell lines and uses thereof |
| WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| US9062106B2 (en) * | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| KR20230114317A (ko) | 2011-07-01 | 2023-08-01 | 암젠 인크 | 포유동물 세포 배양 |
| AR087433A1 (es) * | 2011-08-08 | 2014-03-26 | Merck Sharp & Dohme | Analogos de insulina n-glicosilados |
| CN103946366B (zh) | 2011-09-16 | 2017-08-11 | 安姆根有限公司 | 细胞培养物的预编程非反馈控制的连续供料 |
| US10634589B2 (en) | 2011-10-26 | 2020-04-28 | Amgen Inc. | Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light |
| EP2804946A4 (en) * | 2012-01-20 | 2016-05-25 | Agency Science Tech & Res | RECOMBINANT CHO GMT PROTEIN EXPRESSION |
| WO2013114164A1 (en) * | 2012-01-30 | 2013-08-08 | Dr. Reddy's Laboratories Limited | Method for obtaining glycoprotein composition with increased afucosylation content |
| US10059770B2 (en) | 2012-01-30 | 2018-08-28 | Dr. Reddy's Laboratories Limited | Process of modulating man5 and/or afucosylation content of a glycoprotein composition |
| WO2013138159A1 (en) | 2012-03-15 | 2013-09-19 | Amgen Inc. | Methods of determining exposure to uv light |
| US10481164B2 (en) | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| EP2905290B1 (en) * | 2012-10-05 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Heterodimeric protein composition |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| EP4282975A3 (en) | 2013-07-23 | 2024-02-28 | Biocon Limited | Methods for controlling fucosylation levels in proteins |
| PL3110961T3 (pl) * | 2014-02-27 | 2020-04-30 | F. Hoffmann-La Roche Ag | Modulacja wzrostu i glikozylacji komórek przy uzyskiwaniu rekombinowanych glikoprotein |
| SG11201702964UA (en) * | 2014-10-27 | 2017-05-30 | Agency Science Tech & Res | Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity |
| ES2784503T3 (es) | 2014-12-01 | 2020-09-28 | Amgen Inc | Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína |
-
2015
- 2015-12-01 ES ES15816598T patent/ES2784503T3/es active Active
- 2015-12-01 CA CA2969225A patent/CA2969225C/en active Active
- 2015-12-01 AU AU2015355087A patent/AU2015355087C1/en active Active
- 2015-12-01 EA EA202091598A patent/EA202091598A3/ru unknown
- 2015-12-01 SG SG11201704351WA patent/SG11201704351WA/en unknown
- 2015-12-01 HU HUE15816598A patent/HUE049201T2/hu unknown
- 2015-12-01 DK DK15816598.5T patent/DK3227454T3/da active
- 2015-12-01 JP JP2017547931A patent/JP6698681B2/ja active Active
- 2015-12-01 MX MX2017006997A patent/MX385409B/es unknown
- 2015-12-01 SI SI201531140T patent/SI3227454T1/sl unknown
- 2015-12-01 WO PCT/US2015/063271 patent/WO2016089919A1/en not_active Ceased
- 2015-12-01 PT PT158165985T patent/PT3227454T/pt unknown
- 2015-12-01 EA EA201791223A patent/EA036178B1/ru not_active IP Right Cessation
- 2015-12-01 SG SG10202002458PA patent/SG10202002458PA/en unknown
- 2015-12-01 PL PL15816598T patent/PL3227454T3/pl unknown
- 2015-12-01 CN CN201580071982.6A patent/CN107109455B/zh active Active
- 2015-12-01 EP EP20154019.2A patent/EP3680344A1/en active Pending
- 2015-12-01 US US15/529,950 patent/US10167492B2/en active Active
- 2015-12-01 EP EP15816598.5A patent/EP3227454B1/en not_active Revoked
- 2015-12-01 LT LTEP15816598.5T patent/LT3227454T/lt unknown
- 2015-12-01 IL IL276165A patent/IL276165B/en unknown
- 2015-12-01 KR KR1020177016893A patent/KR102623965B1/ko active Active
-
2017
- 2017-05-29 IL IL252569A patent/IL252569B/en active IP Right Grant
- 2017-05-29 CL CL2017001369A patent/CL2017001369A1/es unknown
- 2017-05-31 ZA ZA2017/03729A patent/ZA201703729B/en unknown
-
2018
- 2018-11-14 US US16/191,352 patent/US20190085370A1/en not_active Abandoned
-
2020
- 2020-02-05 US US16/783,117 patent/US10822630B2/en active Active
- 2020-03-31 AU AU2020202302A patent/AU2020202302A1/en not_active Abandoned
- 2020-04-07 CY CY20201100325T patent/CY1123247T1/el unknown
- 2020-04-30 JP JP2020080270A patent/JP7066775B2/ja active Active
- 2020-09-29 ZA ZA2020/06002A patent/ZA202006002B/en unknown
- 2020-10-02 US US17/062,199 patent/US20210017565A1/en not_active Abandoned
-
2022
- 2022-01-28 AU AU2022200586A patent/AU2022200586A1/en not_active Abandoned
- 2022-04-26 JP JP2022072126A patent/JP2022101669A/ja active Pending
-
2023
- 2023-01-18 US US18/156,025 patent/US20230159974A1/en not_active Abandoned
-
2024
- 2024-04-10 JP JP2024063188A patent/JP2024095777A/ja active Pending
- 2024-06-24 AU AU2024204313A patent/AU2024204313A1/en not_active Abandoned
-
2025
- 2025-09-01 AU AU2025223948A patent/AU2025223948A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3227454T3 (da) | Fremgangsmåde til manipulering af niveauet af glycanindhold på et glycoprotein | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3372584T3 (da) | Fremgangsmåde til fremstillingen af en diarylthiohydantoin-forbindelse | |
| IL247299B (en) | Complement component c5 antibodies | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3094392T3 (da) | Fremgangsmåde til reducering af biobelastningen fra en kromatografiharpiks | |
| DK3126373T3 (da) | Fremgangsmåde til fremstilling af amg 416 | |
| DK3125898T3 (da) | Farmakofor til trail-induktion | |
| DE112015004474A5 (de) | Optoelektronisches Bauelement | |
| DK3206518T3 (da) | Footlet samt en fremgangsmåde til at fremstille en sådan footlet | |
| DK3230929T3 (da) | Forbedringer til tælleranordninger | |
| IL304203A (en) | Complement component c5 antibodies | |
| DK3295941T3 (da) | Fremgangsmåde til fremstilling af form a af grapiprant | |
| DE112015004123A5 (de) | Optoelektronisches Bauteil | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3146044T3 (da) | Fremgangsmåde til immobilisering af en lipase | |
| DK3114053T3 (da) | Maskine til separation af elementer | |
| DE112015002642A5 (de) | Optoelektronisches Bauelement | |
| DK2942098T3 (da) | Forbedret fremgangsmåde til fjernelse af nitrit | |
| DE112015004104A5 (de) | Optoelektronisches Bauteil | |
| DE112015004195A5 (de) | Optoelektronisches bauelement |